Back to Search
ABDULRAHEEM YACOUB, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1639372766IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
2005020355(MO)
Education
OTHER
Class of 2003
Research & Publications (20)
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
PMID 19117997·Cancer Res·2009
7-preclinical
MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism.
PMID 19417161·Mol Cancer Ther·2009
8-other
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
PMID 19483104·Mol Pharmacol·2009
8-other
The rapid molecular subtyping and pathotyping of avian influenza viruses.
PMID 19026689·J Virol Methods·2009
7-preclinical
Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo.
PMID 19276168·Mol Cancer Ther·2009
7-preclinical
Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo.
PMID 18347148·Mol Cancer Ther·2008
8-other
Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo.
PMID 18379195·Cancer Biol Ther·2008
7-preclinical
RLIP76 in defense of radiation poisoning.
PMID 18793957·Int J Radiat Oncol Biol Phys·2008
7-preclinical
Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.
PMID 18544666·Mol Pharmacol·2008
8-other
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
PMID 18765530·Clin Cancer Res·2008
8-other
MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors.
PMID 18376144·Cancer Biol Ther·2008
7-preclinical
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells.
PMID 18281515·Mol Cancer Ther·2008
8-other
PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells.
PMID 18299661·Autophagy·2008
7-preclinical
Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling.
PMID 18281516·Mol Cancer Ther·2008
8-other
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
PMID 18790746·Mol Cancer Ther·2008
7-preclinical
OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.
PMID 18182481·Mol Pharmacol·2008
7-preclinical
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review).
PMID 17912425·Int J Oncol·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2330 SHAWNEE MISSION PARKWAY, SUITE 210, MS 5003
WESTWOOD, KS 66205 - Phone
- (913) 588-6029
Quick Facts
- NPI
- 1639372766
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 23
- Publications
- 20
Are you this provider?
Claim Your Profile